Current Influenza Antiviral Drug Strategy Limitations and Future Development of both Preventative and Intervention Antiviral Therapies


Дәйексөз келтіру

Толық мәтін

Негізгі сөздер

Авторлар туралы

Fahim Ahmad

Department of Infectious Disease, Scientific Platform Division, Southern Research

Хат алмасуға жауапты Автор.
Email: info@benthamscience.net

Әдебиет тізімі

  1. Palese P, Shaw ML. Orthomyxoviridae: The viruses and their replication. In: Fields Virology. 5 th . Philadelphia: Lippincott-Raven Press 2007; pp. 1647-90.
  2. Centers for Disease Control Prevention. 2011. Available from: http://www.cdc.gov/flu/about/disease/index.htm
  3. Shiraishi K, Mitamura K, Sakai-Tagawa Y, Goto H, Sugaya N, Kawaoka Y. High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza. J Infect Dis 2003; 188(1): 57-61. doi: 10.1086/375799 PMID: 12825171
  4. Garten RJ, Davis CT, Russell CA, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009; 325(5937): 197-201. doi: 10.1126/science.1176225 PMID: 19465683
  5. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 2006; 295(8): 891-4. doi: 10.1001/jama.295.8.joc60020 PMID: 16456087
  6. Fang Q, Wang D. Advanced researches on the inhibition of influenza virus by Favipiravir and Baloxavir. Biosaf Heal 2020; 2(2): 64-70. doi: 10.1016/j.bsheal.2020.04.004

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML

© Bentham Science Publishers, 2024